Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Background: Non-alcoholic liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome, and it can progress to non-alcoholic steatohepatitis (NASH). Alterations in the gut microbiome have been implicated in the development of NAFLD/NASH, although the underlying mechanisms remain unclear. Results: We found that the consumption of the prebiotic inulin markedly ameliorated the phenotype of NAFLD/NASH, including hepatic steatosis and fibrosis, in mice. Inulin consumption resulted in global changes in the gut microbiome, including concomitant enrichment of the genera Bacteroides and Blautia, and increased concentrations of short-chain fatty acids, particularly acetate, in the gut lumen and portal blood. The consumption of acetate-releasing resistant starch protected against NAFLD development. Colonisation by Bacteroides acidifaciens and Blautia producta in germ-free mice resulted in synergetic effects on acetate production from inulin. Furthermore, the absence of free fatty acid receptor 2 (FFAR2), an acetate receptor, abolished the protective effect of inulin, as indicated by the more severe liver hypertrophy, hypercholesterolaemia and inflammation. These effects can be attributed to an exacerbation of insulin resistance in the liver, but not in muscle or adipose tissue. Conclusion: These findings demonstrated that the commensal microbiome–acetate–FFAR2 molecular circuit improves insulin sensitivity in the liver and prevents the development of NAFLD/NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 FFAR2 signalling play key roles in hepatic insulin signalling and NAFLD/NASH development. Impairment in the FFAR2-induced enhancement of insulin signalling exacerbates insulin resistance in the liver but not in the adipose tissue or muscle. a Oral glucose tolerance testing performed in WT and Ffar2−/− mice fed an HFC diet for 19 weeks (WT, n = 6; Ffar2−/−, n = 7). b HOMA-IR was calculated according to the following formula: HOMA-IR = {[fasting insulin (mU/ml) − fasting glucose (mg/dl)]/405} (WT, n = 6; Ffar2−/−, n = 7). c Pyruvate tolerance testing performed in WT and Ffar2−/− mice fed an HFC diet for 20 weeks (WT, n = 6; Ffar2−/−, n = 7). d Insulin-stimulated Akt phosphorylation at Ser473 in the liver, muscle and epididymal fat of Ffar2−/− mice fed an HFC diet, after 6 h of fasting (n = 3 each). e Adenovirus-mediated Ffar2 knockdown in the liver increases insulin resistance and triglyceride accumulation in the liver. Male 8-week-old C57BL/6 mice were administered with a control or Ffar2 shRNA adenovirus (Control, n = 8; shFFAR2, n = 7) and were fed an HFC diet for 4 weeks. Pyruvate tolerance testing performed after 16 h of fasting. f Liver triglyceride. g Liver cholesterol. Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student’s t test)](https://figures.cochat.ai/paper-figures/b9d015e79674435895c0d115205fd59f/commensal-microbe-derived-acetate-suppresses-nafld-nash-development-via-hepatic-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Microbial acetate on the other hand, is protective against MASH fibrosis through activation of the free fatty acid receptor 2 (FFAR2) receptor on hepatocytes and modulation of lipid metabolism (208).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“The hepatic lipid fraction was extracted from liver homogenates using the Bligh and Dyer method [54].”
MethodMEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 1×
“8) [53] on genes that with significantly differential expression.”
BackgroundCutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“After trimming both primer sequences using cutadapt [40], following chimera detection using the USEARCH de novo method, the sequences were assigned to OTUs using the UCLUST algorithm with a sequence identity threshold of 97%.”
MethodThe SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055 · cited 1×
“Taxonomic assignments for each OTU were made via similarity searching against the SILVA 16S rRNA gene sequence reference database (v132) [41] using blastn (v2.”
MethodBLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Lane, D. (1991) · Medical Entomology and Zoology · Cited by 11,719
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAFLD activity score was determined as described elsewhere [55, 56].”
Method
Cited by
Ney, L.-M., Wipplinger, M., Grossmann, M., Engert, N., Wegner, V. D., & Mosig, A. S. (2023) · Open Biology · doi:10.1098/rsob.230014 · Cited by 315
Updated mechanisms of MASLD pathogenesis
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02108-x · Cited by 300
“For example, recent studies have evinced that commensal microbe-derived acetate moderates the development of MASLD through the free fatty acid receptor 2 (FFAR2) signaling pathway in mouse models [117].”
BackgroundSong, Q., Zhang, X., Liu, W., Wei, H., Liang, W., Zhou, Y., Ding, Y., Ji, F., Ho-Kwan Cheung, A., Wong, N., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.005 · Cited by 293
Ikeda, T., Nishida, A., Yamano, M., & Kimura, I. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108273 · Cited by 271
Self-citationWei, W., Wong, C. C., Jia, Z., Liu, W., Liu, C., Ji, F., Pan, Y., Wang, F., Wang, G., Zhao, L., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01418-7 · Cited by 248
Metadata
- Authors
- Aoki, R., Onuki, M., Hattori, K., Ito, M., Yamada, T., Kamikado, K., Kim, Y.-G., Nakamoto, N., Kimura, I., Clarke, J. M., Kanai, T., & Hase, K.
- Affiliations
- Keio University (JP)
- Ezaki Glico (Japan) (JP)
- Tokyo University of Agriculture and Technology (JP)
- CSIRO Health and Biosecurity (AU)
- Corresponding author
- Hase, Koji
- Venue
- Microbiome
- Published
- 2021-09-16
- Volume
- 9
- Issue
- 1
- Pages
- 188-188
- ISSN
- 2049-2618 (ISSN-L)
- PMC
- PMC8447789
- OpenAlex
- W3200935965
- Cited by
- 167
- References
- 58
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 48 · 2023: 30 · 2022: 15 · 2021: 2
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Microbiome (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- japan society for the promotion of science (20H00509, 20H05876 and JPJSBP120207405)
- KMEC (FY2015-FY2019)
- Japan Agency for Medical Research and Development (18gm1010004h0103, 19gm1010004s0104, and 20gm1010004h0105)
- japan science and technology agency (Moonshot R&D JPMJMS2025)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, acetate, FFAR2, gut microbiota, inulin, prebiotics, short-chain fatty acids, resistant starch, Bacteroides acidifaciens, Blautia producta, hepatic insulin resistance, hepatic steatosis, liver fibrosis, germ-free mice, hypercholesterolemia
- MeSH terms
- Eubacteriales, Acetates, Animals, Bacteroides, Receptors, G-Protein-Coupled, Mice, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. https://app.cochat.ai/papers/10.1186/s40168-021-01125-7
- The paper
- Aoki, R., Onuki, M., Hattori, K., Ito, M., Yamada, T., Kamikado, K., Kim, Y.-G., Nakamoto, N., Kimura, I., Clarke, J. M., Kanai, T., & Hase, K. (2021). Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. Microbiome. https://doi.org/10.1186/s40168-021-01125-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.